EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 74 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... April 23, 2021 Cancer in My Community: Providing Supportive Care in Serbia October 14, 2021 After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... September 5, 2019 Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors Male Patients with Cancer at Higher Risk of Severe Disease Course... For People with Cancer, Are Steroids the Best Treatment for Breathing...
